Imbed Biosciences Extends Series A Financing to $4 Million to Commercialize Innovative Bioresorbable Bandage

Nov 06 2019

Imbed Biosciences Inc. (Imbed), a privately held biotech company emerging as a leader in the development of advanced therapies for burns, chronic ulcers and surgical wounds, announced today that it has closed its Series A Preferred Stock equity financing, which was expanded to $4 million due to investor demand. The investment round was led by a group of investors organized by Formidable Asset Management and included participation from WISC Partners, the company’s seed investor, as well as additional new investors.